Selective serotonin re-uptake inhibitors: A review of the side effects in adolescents

Australian Family Physician

Volumn 42, Issue 8, 2013, Pages 620-623

  Gordon, Michael ^a   Melvin, Glenn ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Adolescent; Adolescent psychiatry; Adverse drug events; Mental health; Selective serotonin re uptake inhibitors

Indexed keywords

SEROTONIN UPTAKE INHIBITOR;

ABDOMINAL PAIN; ADOLESCENT; ARTICLE; CHEMICALLY INDUCED DISORDER; HEADACHE; HUMAN; INSOMNIA; MENTAL DISEASE; NAUSEA; SUICIDAL IDEATION; SUICIDE ATTEMPT; VOMITING;

ABDOMINAL PAIN; ADOLESCENT; HEADACHE; HUMANS; MENTAL DISORDERS; NAUSEA; SEROTONIN UPTAKE INHIBITORS; SLEEP INITIATION AND MAINTENANCE DISORDERS; SUICIDAL IDEATION; SUICIDE, ATTEMPTED; VOMITING;

EID: 84884125822     PISSN: 03008495     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Nash J, Nutt D. Antidepressants. Psychiatry 2007;6:289-94.
2. Hazell P, O'Connell D, Heathcote D, Henry DA. Tricyclic drugs for depression in children and adolescents. Cochrane Database Syst Rev 2002;2:CD002317.
3. Martin A, Young C, Leckman JF, Mukonoweshuro C, Rosenheck R, Leslie D. Age effects on antidepressant-induced manic conversion. Arch Pediatr Adolesc Med 2004;158:773-80.
4. McManus P, Mant A, Mitchell P, Britt H, Dudley J. Use of antidepressants by general practitioners and psychiatrists in Australia. Aust N Z J Psychiatry 2003;37:184-89.
5. E fron D, Hiscock H, Sewell JR, et al. Prescribing of psychotropic medications for children by Australian pediatricians and child psychiatrists. Pediatrics 2003;111:372-75.
6. L eonard HL, March J, Rickler KC, Allen AJ. Pharmacology of the selective serotonin reuptake inhibitors in children and adolescents. J Am Acad Child Adolesc Psychiatry 1997;36:725-36.
7. E mslie G, Kratochvil C, Vitiello B, et al. Treatment for Adolescents with Depression Study (TADS): Safety Results. J Am Acad Child Adolesc Psychiatry 2006;45:1440-55.
8. Walkup JT, Albano AM, Piacentini J, et al. Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. N Engl J Med 2008;359:2753-66.
9. Melvin GA, Tonge BJ, King NJ, et al. A comparison of cognitive-behavioral therapy, sertraline, and their combination for adolescent depression. J Am Acad Child Adolesc Psychiatry 2006;45:1151-61.
10. Goodyer I, Dubicka B, Wilkinson P, et al. Selective serotonin reuptake inhibitors (SSRIs) and routine specialist care with and without cognitive behaviour therapy in adolescents with major depression: randomised controlled trial. BMJ 2007;335:142.
11. Cheung AH, Emslie GJ, Mayes TL. Review of the efficacy and safety of antidepressants in youth depression. J Child Psychol Psychiatry 2005;46:735-54.
12. N ilsson M, Joliat MJ, Miner CM, et al. Safety of subchronic treatment with fluoxetine for major depressive disorder in children and adolescents. J Child Adolesc Psychopharmacol 2004;14:412-17.
13. Weller EB, Weller RA, Kloos AL, et al. Impact of depression and its treatment on the bones of growing children. Curr Psychiatry Rep 2007;9:94-8.
14. Scharko AM. Selective serotonin reuptake inhibitor-induced sexual dysfunction in adolescents: A Review. J Am Acad Child Adolesc Psychiatry 2004;43:1071-79.
15. Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. J Clin Psychiatry 2001;62 S3:10-21.
16. Goodwin GM, Anderson I, Arango C, et al. ECNP consensus meeting. Bipolar depression. Nice, March 2007. Eur Neuropsychopharmacol 2008;18:535-49.
17. Jain U, Birmaher B, Garcia M, Al-Shabbout M, Ryan N. Fluoxetine in children and adolescents with mood disorders: a chart review of efficacy and adverse effects. J Child Adolesc Psychopharmacology 1992;2:259-65.
18. Tierney E, Joshi PT, Llinas JF, et al. Sertraline for major depression in children and adolescents: preliminary clinical experience. J Child Adolesc Psychopharmacology 1995;5:13-27.
19. Strober M, Carlson G. Bipolar illness in adolescents with major depression: clinical, genetic and psychopharmacological predictors in a three- to four- year prospective follow-up investigation. Arch Gen Psychiatry 1982;39:549-55.
20. King RA, Riddle MA, Chappell PB, et al. Emergence of self-destructive phenomena in children and adolescents during fluoxetine treatment. J Am Acad Child Adolesc Psychiatry 1991;30:179-86.
21. H ammad TA. Review and evaluation of clinical data: TGA; 2004. Available at: http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4065b1-10-TAB08-Hammads-Review.pdf [Accessed 28 June 2013].
22. H ammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 2006;63:332-39.
23. FDA. Labeling Change Request Letter for Antidepressant Medications; 2004. Black box warning of antidepressant medication in children and adolescents]. Available at: http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ ucm096352.htm [Accessed 28 June 2013].
24. Gibbons RD, Brown CH, Hur K, et al. Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry 2007;164:1356-63.
25. B aldessarini RJ, Pompili M, Tondo L. Suicidal risk in antidepressant drug trials. Arch Gen Psychiatry 2006;63:246-48.
26. B ridge JA, Iyengar S, Salary CB, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA 2007;297:1683-96.
27. Gibbons RD, Hur K, Brown CH, et al. Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. Arch Gen Psychiatry 2012;69:572-79.
28. H etrick SE, McKenzie JE, Cox GR, Simmons MB, Merry SN. Newer generation antidepressants for depressive disorders in children and adolescents. Cochrane Database Syst Rev 2012;11:CD004851.
29. O lfson M, Shaffer D, Marcus SC, Greenberg T. Relationship between antidepressant medication treatment and suicide in adolescents. Arch Gen Psychiatry 2003;60:978-82.
30. Isacsson G, Rich CL, Jureidini J, Raven M. The increased use of antidepressants has contributed to the worldwide reduction in suicide rates. Br J Psychiatry 2010;196:429-33.
31. L eon AC, Marzuk PM, Tardiff K, et al. Antidepressants and youth suicide in New York City, 1999-2002. J Am Acad Child Adolesc Psychiatry 2006;45:1054-8.
32. Isacsson G, Holmgren P, Ahlner J. Selective serotonin reuptake inhibitor antidepressants and the risk of suicide: a controlled forensic database study of 14,857 suicides. Acta Psychiatr Scand 2005;111:286-90.
33. Simon GE, Savarino J, Operkalski B, Wang PS. Suicidal risk during antidepressant treatment. Am J Psychiatry 2006;163:41-7.
34. Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviors. JAMA 2004;292:338-43.
35. Valuck RJ, Libby AM, Sills MR, et al. Antidepressant treatment and risk of suicide attempt by adolescents with major depressive disorder: a propensity-adjusted retrospective cohort study. CNS Drugs 2004;18:1119-32.
36. RANZCP, RACGP, RACP. Clinical guidance on the use of antidepressant medication by children and adolescents: RANZCP RACGP RACP; 2005 Available at: www.ranzcp.org/Files/ranzcp-attachments/Resources/College_Statements/ Practice_Guidelines/Clinical_Guidance_on_the_use_of_Antidepressant_med. aspx [Accessed 28 June 2013].
37. Ghanizadeh A, Ghanizadeh M, Seifoori M. Can fluoxetine alone cause serotonin syndrome in adolescents? Psychopharmacol Bull 2008;41:76-9.
38. B oyer EW, Shannon M. The serotonin syndrome. N Engl J Med 2005;352:1112- 20.
39. Gillman PK. The serotonin syndrome and its treatment. J Psychopharmacol 1999;13:100-09.
40. Taylor D, Paton C, Kerwin R. The South London and Maudsley NHS Trust 2003 Prescribing Guidelines. London: Martin Dunitz; 2003.
41. Diler RS, Avci A. Selective serotonin reuptake inhibitor discontinuation syndrome in children: six case reports. Curr Ther Res 2002;63:188-97.
42. B lack K, Shea C, Dursun S, Kutcher S. Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria. J Psychiatry Neurosci 2000;25:255-61.
43. van Geffen EC, Hugtenburg JG, Heerdink ER, van Hulten RP, Egberts AC. Discontinuation symptoms in users of selective serotonin reuptake inhibitors in clinical practice: tapering versus abrupt discontinuation. Eur J Clin Pharmacol 2005;61:303-07.